CN1142786C - Medicine for treating coronary heart disease - Google Patents
Medicine for treating coronary heart disease Download PDFInfo
- Publication number
- CN1142786C CN1142786C CNB001377205A CN00137720A CN1142786C CN 1142786 C CN1142786 C CN 1142786C CN B001377205 A CNB001377205 A CN B001377205A CN 00137720 A CN00137720 A CN 00137720A CN 1142786 C CN1142786 C CN 1142786C
- Authority
- CN
- China
- Prior art keywords
- radix
- medicine
- gram
- weight portions
- heart disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 48
- 208000029078 coronary artery disease Diseases 0.000 title claims abstract description 13
- 229940079593 drug Drugs 0.000 title description 14
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 12
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 12
- 241000208340 Araliaceae Species 0.000 claims abstract description 11
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 11
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 11
- 235000008434 ginseng Nutrition 0.000 claims abstract description 11
- 239000000843 powder Substances 0.000 claims description 13
- 239000009636 Huang Qi Substances 0.000 claims description 11
- 239000002775 capsule Substances 0.000 claims description 5
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- IZEKFCXSFNUWAM-UHFFFAOYSA-N dipyridamole Chemical compound C=12N=C(N(CCO)CCO)N=C(N3CCCCC3)C2=NC(N(CCO)CCO)=NC=1N1CCCCC1 IZEKFCXSFNUWAM-UHFFFAOYSA-N 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 abstract description 7
- 239000000203 mixture Substances 0.000 abstract description 7
- 208000010125 myocardial infarction Diseases 0.000 abstract description 5
- 235000014375 Curcuma Nutrition 0.000 abstract description 3
- 238000005516 engineering process Methods 0.000 abstract description 3
- 244000164480 Curcuma aromatica Species 0.000 abstract 2
- 240000007164 Salvia officinalis Species 0.000 abstract 2
- 240000001398 Typha domingensis Species 0.000 abstract 2
- 229940107666 astragalus root Drugs 0.000 abstract 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 abstract 2
- 235000005412 red sage Nutrition 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000002107 myocardial effect Effects 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 230000001954 sterilising effect Effects 0.000 description 6
- 238000004659 sterilization and disinfection Methods 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 5
- 239000012567 medical material Substances 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000001035 drying Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical group C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 2
- 206010002660 Anoxia Diseases 0.000 description 2
- 241000976983 Anoxia Species 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- 229910000831 Steel Inorganic materials 0.000 description 2
- 230000007953 anoxia Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000006706 cellular oxygen consumption Effects 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000010959 steel Substances 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- 206010003225 Arteriospasm coronary Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 244000164439 Curcuma angustifolia Species 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 208000019804 backache Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to medicine for treating coronary disease. The medicine is medicine formed by preparing ginseng, notoginseng, astragalus root, cattail pollen, red sage root and curcuma root based on specific technology. The medicine composition of the present invention has preferred weight proportion of 100 weight portions of ginseng, 100 weight portions of astragalus root, 50 weight portions of cattail pollen, 50 weight portions of red sage root and 50 weight portions of curcuma root. The medicine has good therapeutic effects on treating coronary disease, angina pectoris and myocardial infarction.
Description
The present invention relates to a kind of Chinese patent medicine for the treatment of coronary heart disease, is to be active ingredient with the Chinese herbal medicine specifically, and the medicine according to special process is prepared from has good curative effect to coronary heart disease, angina pectoris, myocardial infarction.
Coronary heart disease belongs to the disease of Chinese medicine categories such as " angina pectoris, the thoracic obstruction ".The serious harm person in middle and old age are healthy, though carried out extensive, deep research at present both at home and abroad,, aspect treating both the principal and secondary aspects of a disease, still exist a lot of problems to need to be resolved hurrily.For this reason, we are according to motherland's traditional medical theory, through clinical practice for many years, taked blood circulation promoting and blood stasis dispelling, fragrance is invigorated blood circulation, method such as invigorate blood circulation that temperature is logical, in addition comprehensive utilization flexibly, through screening and experimentation, invented a kind of medicine for the treatment of coronary heart disease, angina pectoris, myocardial infarction to multiple Chinese herbal medicine.
The object of the invention provides a kind of medicine for the treatment of coronary heart disease, angina pectoris, myocardial infarction.
Coronary heart disease belongs to empty this reality of mark more, blood stasis due to qi deficiency person for seeing more, the inventor combines motherland's traditional medicine with the modern Chinese medicine theory, through research and clinical practice for many years, successively many blood-activating and stasis-removing have been carried out the research of serial system, therefrom select Radix Ginseng, Radix Notoginseng, the Radix Astragali, Pollen Typhae, Radix Salviae Miltiorrhizae, medicines such as Radix Curcumae are compatible, carried out systematic comparison and practical studies, the confirmer participates in Radix Notoginseng as a result, the Radix Astragali, Pollen Typhae, Radix Salviae Miltiorrhizae, the Radix Curcumae compatibility is better than other combinations, on this basis, carry out clinical observation again, confirm that this medical instrument has dosage few, be easy to preparation, taking convenience, good analgesic effect, get and imitate rapidly, have the advantage for the treatment of both the principal and secondary aspects of a disease, adhere to taking by the course of treatment, the patient thinks that all the clothes back is uncomfortable in chest, chest pain, it is tired to breathe hard, all very fast disappearance of diseases such as palpitation and insomnia.To the coronary heart disease determined curative effect of Qi deficiency blood stasis type, be better than other similar medicines.
Medicine of the present invention is to be the Chinese patent medicine that feedstock production forms with following drug regimen.
Radix Ginseng 100-200, Radix Notoginseng 100-200, Radix Astragali 100-200, Pollen Typhae 50-100, Radix Salviae Miltiorrhizae 50-100, Radix Curcumae 50-100 weight portion.
The preferred weight proportioning of pharmaceutical composition of the present invention is: Radix Ginseng 100, Radix Notoginseng 100, the Radix Astragali 100, Pollen Typhae 50, Radix Salviae Miltiorrhizae 50, Radix Curcumae 50 weight portions.
Pharmaceutical composition of the present invention can be prepared into any pharmaceutical preparation that is suitable for using clinically according to conventional formulation technology.As: tablet powder, pill, granule, capsule, oral liquid etc.
Pharmaceutical composition of the present invention can directly prepare patent medicine, also can extract respectively each group in the compositions, prepares patent medicine then, and these are all within protection scope of the present invention.
The preparation method of medicine capsule of the present invention is:
1, selected crude drug: selected high-quality Chinese crude drug, remove impurity, and differentiate with run-of-the-mill by pharmacopeia regulation and to check.Of poor quality, rotten, to damage by worms, defective work medical material such as go mouldy must not use.
2, dried: with medical materials such as Radix Ginseng, Radix Notoginseng, the Radix Astragali, Pollen Typhae, Radix Salviae Miltiorrhizae, Radix Curcumaes, place the stainless (steel) wire dish respectively, send in the digital display air dry oven, temperature is transferred at 60 ℃ of constant temperature, smoke 30 minutes till crude drug parches.
3, coarse powder: the Chinese medicine grinder mesh screen is configured to 40 orders,, sends into respectively and carry out coarse powder in the pulverizer, get 40 order coarse powder the good crude drug of drying, standby.
4, smart powder: the micro jet mesh screen is configured to 150 orders,, sends in the jet mill, make 150 purpose fine powders the coarse powder that processes, standby.
5, be mixed: put into behind the Chinese medicine mixer mix homogeneously medical material that crushes standby.
6, sterilization treatment: the medicine of mix homogeneously is put into clean charging tray, send in the sterilization cabinet and carried out sterilization treatment 2 hours, it is standby that sterile bag is put in taking-up.
7, capsule formulation: will be through the fine drug powder of sterilization, in No. 1 capsule of packing into promptly.
Pharmaceutical composition of the present invention, having lives is equipped with blood stasis dispelling, and fragrance is invigorated blood circulation, and the function that nourishes heart and promote blood circulation cures mainly uncomfortable in chest that blood stasis due to qi deficiency causes, breathes hard, the pained back of the body of infusing, the heart is infused in backache, and diseases such as limb fiber crops belong to the thoracic obstruction, angina pectoris.More be applicable to the coronary heart disease of blood stasis due to qi deficiency, angina pectoris, diseases such as myocardial infarction.
Prove that through the zoopery pharmacodynamic study pharmaceutical composition of the present invention has following pharmacological action:
One, to the influence of isolated rat heart perfusion
1, to the influence of the rat heart of normally leaving one's post.
Experiment is divided into four groups, matched group, two dosage groups of administration group and isoptin group.Experimental result confirms that this medicine can obviously increase coronary flow, and sustainable 29 minutes, myocardial contraction there is inhibitory action.
2, to the influence of the rat heart ischemia model of leaving one's post.
Experiment is divided into matched group, two dosage groups of administration group and isoptin group.The result confirms that the hat flow that medicine of the present invention can obviously be alleviated due to the coronary spasm reduces, and suppresses myocardial contraction, conserve energy consumption.
Two, to cultivating the influence of the scarce sugar damage of neonatal rat myocardial cell oxygen consumption and anoxia.
1, to the influence of oxygen consumption: medicine of the present invention can obviously suppress isoproterenol increases the myocardial cell oxygen consumption, and the mechanism that it resists myocardial ischemia is described, part is to act on cellular level.
2, to cultivating the protective effect of the scarce sugar damage of neonatal rat myocardial cell anoxia, prove that this medicine plays direct protective action to its damage.
3, to cultivating the influence of myocardial cell oxygen contradiction, experimental result shows that damage has significant protective effect to this pharmaceutical composition to oxygen contradiction on cellular level.
Embodiment:
Prescription: Radix Ginseng: 100 grams
Radix Notoginseng: 100 grams
The Radix Astragali: 100 grams
Pollen Typhae: 50 grams
Radix Salviae Miltiorrhizae: 50 grams
Radix Curcumae: 50 grams
Technology:
After the crude drug check, taking by weighing, selected high-quality Radix Ginseng, Radix Notoginseng, the Radix Astragali, Pollen Typhae, all medicines such as Radix Salviae Miltiorrhizae, Radix Curcumae.
With above-mentioned medical material, place the stainless (steel) wire dish respectively, send in the drying machine, temperature is adjusted to more than 60 ℃, dried by the fire 30 minutes, till crude drug parches.
The Chinese medicine grinder mesh screen is configured to 40 orders, the good crude drug of drying is sent into respectively carried out coarse powder in the pulverizer.
The micro jet mesh screen is configured to 150 orders, the coarse powder that processes.Send into that to make 150 order fine powders in the jet mill standby.
The medical material fine powder that crushes is put into Chinese medicine mixer mix homogeneously, standby.
The medicine of mix homogeneously is put into clean charging tray, send in the sterilization cabinet and carried out sterilization treatment 2 hours, it is standby that sterile bag is put in taking-up.
To make medicine packs in No. 1 capsule promptly.
Claims (3)
1, a kind of coronary heart disease, anginal Chinese medicine is characterized in that this medicine is with Radix Ginseng, Radix Notoginseng, the Radix Astragali, Pollen Typhae, Radix Salviae Miltiorrhizae, Radix Curcumae, the medicament that is prepared from according to following proportioning:
Radix Ginseng 100-200 gram, Radix Notoginseng 100-200 gram, Radix Astragali 100-200 gram, Pollen Typhae 50-100 gram, Radix Salviae Miltiorrhizae 50-100 gram, Radix Curcumae 50-100 gram, weight portion.
2, Chinese medicine according to claim 1 is characterized in that the proportioning that the people participates in Radix Notoginseng, the Radix Astragali, Pollen Typhae, Radix Salviae Miltiorrhizae, Radix Curcumae is:
Radix Ginseng 100, Radix Notoginseng 100, the Radix Astragali 100, Pollen Typhae 50, Radix Salviae Miltiorrhizae 50, Radix Curcumae 50, weight portion.
3, according to the Chinese medicine of claim 1 or 2, the dosage form that it is characterized in that this medicine is any of tablet, powder, pill, capsule, granule, oral liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB001377205A CN1142786C (en) | 2000-12-23 | 2000-12-23 | Medicine for treating coronary heart disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB001377205A CN1142786C (en) | 2000-12-23 | 2000-12-23 | Medicine for treating coronary heart disease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1319404A CN1319404A (en) | 2001-10-31 |
| CN1142786C true CN1142786C (en) | 2004-03-24 |
Family
ID=4597785
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB001377205A Expired - Fee Related CN1142786C (en) | 2000-12-23 | 2000-12-23 | Medicine for treating coronary heart disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1142786C (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100444890C (en) * | 2004-11-04 | 2008-12-24 | 苗毅韧 | Chinese medicinal formulation for restoring cardiac muscle function and adjusting blood pressure and preparation method thereof |
| CN101856480B (en) * | 2010-06-01 | 2011-08-10 | 张桂忠 | Chinese medicament for treating myocardial infarction |
| CN103142941B (en) * | 2012-03-31 | 2014-07-23 | 陈欣 | Traditional Chinese medicine composition capsule for treating myocardial infarction and preparation method thereof |
| CN109528881A (en) * | 2019-01-07 | 2019-03-29 | 魏群 | Chinese medicine composition, preparation method and applications |
-
2000
- 2000-12-23 CN CNB001377205A patent/CN1142786C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1319404A (en) | 2001-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1051237C (en) | Meicinal prepn. "Kexianling" for curing epilepsy | |
| CN102225183B (en) | A Chinese medicinal composition for treating cancer, and its preparation method | |
| CN1140279C (en) | Blood-cleaning pill | |
| CN1142786C (en) | Medicine for treating coronary heart disease | |
| CN100386106C (en) | Medicine for treating acne and its preparation | |
| CN102973758A (en) | Traditional Chinese medicine composition for treating depression | |
| US12115204B2 (en) | Compound preparation for neuranagenesis, and preparation method therefor and use thereof | |
| CN103239674B (en) | Antineoplastic traditional Chinese medicine composition and preparation method thereof | |
| CN1296087C (en) | Compound capsule for treating apoplexy involving the meridians of wind phlegm stasis blockage syndrome type and preparation process thereof | |
| CN101991659A (en) | Preparation with functions of clearing heat and releasing toxin and preparation method | |
| CN1148207C (en) | Medicine for strengthening physique and resisting senility | |
| CN101007113B (en) | Shenling Chinese medicine preparation for treating acute and chronic hepatitis and its preparation method | |
| CN101744906A (en) | Applications of Chinese medicinal composition to preparation of medicament for treating facial paralysis | |
| CN1931282A (en) | Chinese medicine composition for promoting blood circulation to eliminate spots and its prepn process | |
| CN110548099A (en) | Traditional Chinese medicine composition for treating coronary heart disease stable angina pectoris and preparation method thereof | |
| CN117018144B (en) | A Chinese medicine composition and its pharmaceutical use | |
| CN103479712B (en) | Traditional Chinese medicine composition for treating coronary heart disease angina and application thereof | |
| CN102091135A (en) | Bezoar antidotal pills (tables and capsules) containing bezoar cultured in vitro and preparation method thereof | |
| CN101991645A (en) | Preparation for treating coronary heart disease and preparation method thereof | |
| CN1238013C (en) | Myocarditis treating Chinese medicine prepn | |
| CN100560087C (en) | Pharmaceutical composition for treating malignant tumors and preparation method thereof | |
| CN107802681B (en) | Composition for improving clinical symptom sign of HIV infected person | |
| CN106943506B (en) | A pharmaceutical composition for treating climacteric syndrome, and its preparation method | |
| CN1141113C (en) | Chinese patent medicine for curing peptic ulcer | |
| CN104906360A (en) | Traditional Chinese medicine compound capable of nourishing Yin and promoting blood circulation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |